Related references
Note: Only part of the references are listed.STING signaling activation inhibits HBV replication and attenuates the severity of liver injury and HBV-induced fibrosis
Yuqi Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2022)
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2022)
Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020)
Nan-Nan Chen et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity
Dae-Shik Kim et al.
CHEMMEDCHEM (2021)
The Complexity of the cGAS-STING Pathway in CNS Pathologies
Amelia L. Fryer et al.
FRONTIERS IN NEUROSCIENCE (2021)
Targeting Innate Immunity in Cancer Therapy
Srikrishnan Rameshbabu et al.
VACCINES (2021)
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
Su Chul Jang et al.
COMMUNICATIONS BIOLOGY (2021)
STING Agonists as Cancer Therapeutics
Afsaneh Amouzegar et al.
CANCERS (2021)
Sonoporation-Enhanced Delivery of STING Agonist Induced Robust Immune Modulation and Tumor Regression
Jun Xu et al.
ADVANCED THERAPEUTICS (2021)
Turning cold tumors into hot tumors by improving T-cell infiltration
Yuan-Tong Liu et al.
THERANOSTICS (2021)
The cGAS-STING pathway as a therapeutic target in inflammatory diseases
Alexiane Decout et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Daniel S. Leventhal et al.
NATURE COMMUNICATIONS (2020)
Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway
Chunyong Ding et al.
ACTA PHARMACEUTICA SINICA B (2020)
cGAS-STING, an important pathway in cancer immunotherapy
Minlin Jiang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Cancer Research: The Lessons to Learn from COVID-19
Chris Bailey et al.
CANCER DISCOVERY (2020)
Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
Henrique Lemos et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape
Liyang Lyu et al.
NATURE BIOTECHNOLOGY (2020)
STING, DCs and the link between innate and adaptive tumor immunity
Ralph E. Vatner et al.
MOLECULAR IMMUNOLOGY (2019)
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Hannah Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers
Carminia Maria Della Corte et al.
CANCER DISCOVERY (2019)
STING activation in cancer immunotherapy
Ting Su et al.
THERANOSTICS (2019)
Global patent landscape of programmed cell death 1: implications of the rapid expansion
Xiangjun Kong et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Patent mining and landscaping of emerging recombinant factor VIII through network analysis
Cristiano Goncalves Pereira et al.
NATURE BIOTECHNOLOGY (2018)
LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
K J Harrington et al.
ANNALS OF ONCOLOGY (2018)
Design of amidobenzimidazole STING receptor agonists with systemic activity
Joshi M. Ramanjulu et al.
NATURE (2018)
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Kelsey E. Sivick et al.
CELL REPORTS (2018)
Preclinical studies of SB 11285, a novel STING agonist for immuno-oncology.
Sreerupa Valli Challa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Henrique Lemos et al.
CANCER RESEARCH (2016)
Suppression of systemic autoimmunity by the innate immune adaptor STING
Shruti Sharma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases
Daxing Gao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation
Siqi Liu et al.
SCIENCE (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations
Nadia Jeremiah et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF-κB Activation through TBK1
Takayuki Abe et al.
JOURNAL OF VIROLOGY (2014)
The global intellectual property landscape of induced pluripotent stem cell technologies
MacKenna Roberts et al.
NATURE BIOTECHNOLOGY (2014)
Activated STING in a Vascular and Pulmonary Syndrome
Y. Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING
Andrea Ablasser et al.
NATURE (2013)
Prediction of emerging technologies based on analysis of the US patent citation network
Peter Erdi et al.
SCIENTOMETRICS (2013)
Autoimmunity Initiates in Nonhematopoietic Cells and Progresses via Lymphocytes in an Interferon-Dependent Autoimmune Disease
Alevtina Gall et al.
IMMUNITY (2012)
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Hiroki Ishikawa et al.
NATURE (2009)
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Hiroki Ishikawa et al.
NATURE (2008)
Share Paper
